Successful pre-clinical validation brings Distalmotion’s surgical robot one-step closer to commercialization

Press Release

Dexter validation confirms Distalmotion’s surgical robot is safe for use and meets surgeons and nurses expectations.

  •  Around 20 surgeons and 20 nurses from leading European hospitals, across urology, gynaecology and general surgery participated in pre-clinical validation of Dexter between end of February and early March 2020.
  • Surgical teams successfully performed surgical procedures using Dexter in a cadaveric setting, including draping, docking, suturing, dissection, switching between laparoscopy and robotics, instrument removal and emergency scenarios.

LAUSANNE, 30 March 2020: Distalmotion, a Swiss-based medical device company removing the complexity out of robotic surgery to fast track its widespread adoption in minimally invasive surgical care, announced today the successful validation of its surgical robot Dexter. By confirming that Dexter is safe for use and meets surgeons and nurses requirements the successful validation brings Distalmotion’s surgical robot one-step closer to commercialization.

The company announced that between February and March 2020, 17 surgeons and 16 nurses from leading European hospitals, across urology, gynecology and general surgery, participated in the first steps of Dexter’s validation. In this phase, surgical teams successfully performed surgical procedures using Distalmotion’s surgical robot, including draping, docking, switching between laparoscopy and robotics, instrument removal and emergency scenarios. This phase confirmed Dexter performs as intended and can be used safely. As a second step, two urologists and three general surgeons performed eight full cadaveric procedures: 1 Nissen-fundoplication, 1 partial cystectomy, 3 cholecystectomies, 1 radial nephrectomy, 1 partial gastrectomy and 1 sigmoid mobilization.

Speaking about Dexter’s successful validation, Michael Friedrich, Distalmotion CEO, said, “This validation study is a major milestone towards Dexter’s go-to-market phase. We are now setting our sight on final testing and verification before regulatory approval and commercialization. Today’s announcement brings us one step closer to our vision of establishing a new global standard of care allowing everyone to access the benefits of robotic surgery.”